Free Trial
→ The chokepoint supplier behind SpaceX's $1.75 trillion empire (From Behind the Markets) (Ad)tc pixel Free AXDX Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Accelerate Diagnostics (AXDX) Competitors

Accelerate Diagnostics logo
Compare

AXDX vs. STAI, SMIT, TBIO, SPEC, and THMO

Should you be buying Accelerate Diagnostics stock or one of its competitors? The main competitors of Accelerate Diagnostics include ScanTech AI Systems (STAI), Schmitt Industries (SMIT), Telesis Bio (TBIO), Spectaire (SPEC), and ThermoGenesis (THMO). These companies are all part of the "measuring and control equipment" industry.

How does Accelerate Diagnostics compare to ScanTech AI Systems?

Accelerate Diagnostics (NASDAQ:AXDX) and ScanTech AI Systems (NASDAQ:STAI) are both small-cap measuring and control equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

17.1% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 74.0% of ScanTech AI Systems shares are held by institutional investors. 43.6% of Accelerate Diagnostics shares are held by insiders. Comparatively, 2.3% of ScanTech AI Systems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ScanTech AI Systems has lower revenue, but higher earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than ScanTech AI Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Accelerate Diagnostics$11.70M0.07-$61.62M-$2.34N/A
ScanTech AI Systems$1.88M0.29-$23.07M-$9.20N/A

Accelerate Diagnostics has a net margin of -471.83% compared to ScanTech AI Systems' net margin of -477.09%. Accelerate Diagnostics' return on equity of 0.00% beat ScanTech AI Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
Accelerate Diagnostics-471.83% N/A -191.66%
ScanTech AI Systems -477.09%-11.25%209.23%

Accelerate Diagnostics has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, ScanTech AI Systems has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accelerate Diagnostics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
ScanTech AI Systems
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Accelerate Diagnostics' average media sentiment score of 0.95 beat ScanTech AI Systems' score of 0.00 indicating that Accelerate Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
Accelerate Diagnostics Positive
ScanTech AI Systems Neutral

Summary

ScanTech AI Systems beats Accelerate Diagnostics on 7 of the 13 factors compared between the two stocks.

How does Accelerate Diagnostics compare to Schmitt Industries?

Schmitt Industries (NASDAQ:SMIT) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap measuring and control equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Accelerate Diagnostics' average media sentiment score of 0.95 beat Schmitt Industries' score of 0.00 indicating that Accelerate Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
Schmitt Industries Neutral
Accelerate Diagnostics Positive

Schmitt Industries has higher earnings, but lower revenue than Accelerate Diagnostics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schmitt Industries$9.89M0.01-$3.28MN/AN/A
Accelerate Diagnostics$11.70M0.07-$61.62M-$2.34N/A

17.1% of Accelerate Diagnostics shares are owned by institutional investors. 17.1% of Schmitt Industries shares are owned by insiders. Comparatively, 43.6% of Accelerate Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Schmitt Industries has a beta of -0.56, meaning that its share price is 156% less volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.

Schmitt Industries has a net margin of 0.00% compared to Accelerate Diagnostics' net margin of -471.83%.

Company Net Margins Return on Equity Return on Assets
Schmitt IndustriesN/A N/A N/A
Accelerate Diagnostics -471.83%N/A -191.66%

Summary

Accelerate Diagnostics beats Schmitt Industries on 6 of the 9 factors compared between the two stocks.

How does Accelerate Diagnostics compare to Telesis Bio?

Telesis Bio (NASDAQ:TBIO) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Telesis Bio has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A
Accelerate Diagnostics$11.70M0.07-$61.62M-$2.34N/A

Telesis Bio has a net margin of -336.59% compared to Accelerate Diagnostics' net margin of -471.83%.

Company Net Margins Return on Equity Return on Assets
Telesis Bio-336.59% N/A -61.89%
Accelerate Diagnostics -471.83%N/A -191.66%

37.6% of Telesis Bio shares are held by institutional investors. Comparatively, 17.1% of Accelerate Diagnostics shares are held by institutional investors. 24.5% of Telesis Bio shares are held by insiders. Comparatively, 43.6% of Accelerate Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Telesis Bio had 1 more articles in the media than Accelerate Diagnostics. MarketBeat recorded 1 mentions for Telesis Bio and 0 mentions for Accelerate Diagnostics. Accelerate Diagnostics' average media sentiment score of 0.95 beat Telesis Bio's score of 0.00 indicating that Accelerate Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
Telesis Bio Neutral
Accelerate Diagnostics Positive

Telesis Bio has a beta of 2.49, indicating that its share price is 149% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500.

Summary

Telesis Bio beats Accelerate Diagnostics on 8 of the 12 factors compared between the two stocks.

How does Accelerate Diagnostics compare to Spectaire?

Spectaire (NASDAQ:SPEC) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap measuring and control equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

26.5% of Spectaire shares are held by institutional investors. Comparatively, 17.1% of Accelerate Diagnostics shares are held by institutional investors. 25.4% of Spectaire shares are held by company insiders. Comparatively, 43.6% of Accelerate Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Accelerate Diagnostics' average media sentiment score of 0.95 beat Spectaire's score of 0.00 indicating that Accelerate Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
Spectaire Neutral
Accelerate Diagnostics Positive

Spectaire has a beta of -6.91, suggesting that its share price is 791% less volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500.

Spectaire has higher earnings, but lower revenue than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Spectaire, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpectaireN/AN/A$8.95M-$0.30N/A
Accelerate Diagnostics$11.70M0.07-$61.62M-$2.34N/A

Spectaire has a net margin of 0.00% compared to Accelerate Diagnostics' net margin of -471.83%. Accelerate Diagnostics' return on equity of 0.00% beat Spectaire's return on equity.

Company Net Margins Return on Equity Return on Assets
SpectaireN/A -81.22% 304.57%
Accelerate Diagnostics -471.83%N/A -191.66%

Summary

Spectaire beats Accelerate Diagnostics on 6 of the 11 factors compared between the two stocks.

How does Accelerate Diagnostics compare to ThermoGenesis?

ThermoGenesis (NASDAQ:THMO) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

5.8% of ThermoGenesis shares are owned by institutional investors. Comparatively, 17.1% of Accelerate Diagnostics shares are owned by institutional investors. 78.0% of ThermoGenesis shares are owned by company insiders. Comparatively, 43.6% of Accelerate Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Accelerate Diagnostics' average media sentiment score of 0.95 beat ThermoGenesis' score of 0.00 indicating that Accelerate Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
ThermoGenesis Neutral
Accelerate Diagnostics Positive

ThermoGenesis has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500.

ThermoGenesis has higher earnings, but lower revenue than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A
Accelerate Diagnostics$11.70M0.07-$61.62M-$2.34N/A

ThermoGenesis has a net margin of 0.00% compared to Accelerate Diagnostics' net margin of -471.83%.

Company Net Margins Return on Equity Return on Assets
ThermoGenesisN/A N/A N/A
Accelerate Diagnostics -471.83%N/A -191.66%

Summary

ThermoGenesis beats Accelerate Diagnostics on 6 of the 11 factors compared between the two stocks.

Get Accelerate Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AXDX vs. The Competition

Export
MetricAccelerate DiagnosticsAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$857K$92K$6.24B$11.86B
Dividend YieldN/AN/A2.73%5.21%
P/E Ratio-0.01N/A29.0428.48
Price / Sales0.070.00477.1060.43
Price / CashN/AN/A27.6236.52
Price / Book-0.020.369.676.67
Net Income-$61.62M-$47.72M$3.55B$332.64M

Accelerate Diagnostics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AXDX
Accelerate Diagnostics
N/A$0.03
flat		N/AN/A$857K$11.70MN/A220
STAI
ScanTech AI Systems
N/A$0.11
-2.2%		N/AN/A$619K$1.88MN/AN/A
SMIT
Schmitt Industries
N/A$0.03
flat		N/AN/A$105K$9.89MN/A160
TBIO
Telesis Bio
N/A$0.05
flat		N/AN/A$92K$225.09MN/A200
SPEC
Spectaire
N/A$0.00
flat		N/AN/A$9KN/AN/A8

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AXDX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel